Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension
Authors:
- Qing LiQLQing Li
- Allison BarrettABAllison Barrett
- Arnaud TiberghienATArnaud Tiberghien
- Keith W. RickertKRKeith W. Rickert
- Kevin L. AllenKAKevin L. Allen
- R. Jim ChristieRCR. Jim Christie
- Marcello MarelliMMMarcello Marelli
- Jay HarperJHJay Harper
- Herren WuHWHerren Wu
- 26 March 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (4) , 1232-1243
Abstract
Despite some clinical success with antibody-drug conjugates (ADCs) in patients with solid tumors and hematological malignancies, improvements in ADC design are still desirable due to the narrow therapeutic window of these compounds. Tumor-targeting antibody fragments have distinct advantages over monoclonal antibodies, including more rapid tumor accumulation and enhanced penetration, but are subject to rapid clearance. Half-life extension technologies such as PEGylation and albumin-binding domains (ABDs) have been widely used to improve the pharmacokinetics of many different types of biologics. PEGylation improves pharmacokinetics by increasing hydrodynamic size to reduce renal clearance, whereas ABDs extend half-life via FcRn-mediated recycling. In this study, we used an anti-oncofetal antigen 5T4 diabody conjugated with a highly potent cytotoxic pyrrolobenzodiazepine (PBD) warhead to assess and compare the effects of PEGylation and albumin binding on the in vivo efficacy of antibody fragment drug conjugates. Conjugation of 2× PEG20K to a diabody improved half-life from 40 min to 33 h, and an ABD-diabody fusion protein exhibited a half-life of 45 h in mice. In a xenograft model of breast cancer MDA-MB-436, the ABD-diabody-PBD showed greater tumor growth suppression and better tolerability than either PEG-diabody-PBD or diabody-PBD. These results suggest that the mechanism of half-life extension is an important consideration for designing cytotoxic antitumor agents.Keywords
Funding Information
- AstraZeneca
This publication has 53 references indexed in Scilit:
- Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimersNucleic Acids Research, 2011
- Site-Specific Conjugation of Monodispersed DOTA-PEGn to a Thiolated Diabody Reveals the Effect of Increasing PEG Size on Kidney Clearance and Tumor Uptake with Improved 64-Copper PET ImagingBioconjugate Chemistry, 2011
- SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor ActivityCancer Research, 2010
- Native albumin for targeted drug deliveryExpert Opinion on Drug Delivery, 2010
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- Biodistribution and tumor imaging of an anti-CEA single-chain antibody–albumin fusion proteinNuclear Medicine and Biology, 2008
- Factors determining antibody distribution in tumorsTrends in Pharmacological Sciences, 2008
- Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2Clinical Cancer Research, 2007
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005